-
01/11/10Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors
-
12/23/09Jennerex Announces Presentations at Upcoming Conferences
-
11/18/09Jennerex and Lee’s Pharmaceuticals Announce Partnership jor JX-594 in China
-
10/19/09Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
-
09/18/09Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
Clinical Trial Programs with Lead Product Jx-594 Funded Through 2010 -
08/11/09Jennerex Closes $5 Million First Tranche of Series C Financing
Clinical Trial Programs Funded Through 2010 -
06/11/09Jennerex Therapeutic Research Collaboration with Ottawa Hospital Research Institute Selected for $10 Million Grant from Ontario Institute for Cancer Research
-
02/10/09Nature Reviews Publishes Article about Jennerex’s Multi-mechanistic Cancer Therapeutic
-
01/13/09Jennerex Appoints Samantha Miller as Vice President of Corporate Development
-
01/12/09Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
-
11/04/08Jennerex To Present at Rodman & Renshaw 10th Annual Healthcare Conference
- 10/15/08Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial with Intravenous Delivery of JX-594 Oncolytic Virus
- 09/09/08Jennerex Completes $8.3 Million Series B Financing and Appoints
Dr. Cal Stiller as Director - 07/16/08Jennerex Publishes Clinical Trial Data with Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated
Hepatitis B Virus - 06/02/08Jennerex Clinical Trial Data with JX-594 Selected for Plenary Session Presentation at Major International Conference
- 05/21/08Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
- 11/08/07Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
- 10/23/07Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
- 10/17/06Jennerex and Green Cross Enter Agreement to Develop and Commercialize JX-594 In South Korea